KT
KTTA.US Pasithea Therapeutics Corp
- Market cap
- USD 17.4M
- P/E
- -
- P/B
- 0.35x
- ROE
- -20.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is KTTA.US undervalued?
Graham numberThe Graham number of Pasithea Therapeutics Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pasithea Therapeutics Corp fundamental analysis
No fundamental analysis for Pasithea Therapeutics Corp yet.
Pasithea Therapeutics Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pasithea Therapeutics Corp
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 dr…
Full company profilePasithea Therapeutics Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pasithea Therapeutics Corp annual financial statements
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 15.1K | 487K | 487K | 0.00 | 0.00 | - |
| Gross Profit | - | -2.21K | -5.09K | -648K | -649K | -663K | - |
| Operating Income | -61.5K | -4.51M | -12.6M | -16.0M | -14.2M | -20.9M | -9.31B |
| EBITDA | -41.0K | -2.17M | -11.7M | -15.3M | -13.6M | -20.2M | -9.31B |
| Net Income | -61.5K | -2.17M | -13.9M | -16.0M | -13.9M | -20.4M | -8.78B |
| EPS | -0.09 | -4.18 | -11 | -13 | -13 | -2.91 | -263 |
| Balance Sheet | |||||||
| Total Assets | 248K | 53.3M | 45.2M | 26.1M | 16.1M | 60.2M | 46.5B |
| Total Liabilities | 6.60K | 1.90M | 2.68M | 2.72M | 1.28M | 5.02M | 2.76B |
| Shareholders' Equity | 241K | 51.4M | 42.5M | 23.4M | 14.8M | 55.2M | 43.7B |
| Cash & Short-term Investments | 244K | 53.0M | 33.1M | 16.3M | 6.92M | 55.2M | 41.2B |
| Total Debt | - | - | 504K | 81.7K | - | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -38.7K | -3.17M | -13.7M | -13.4M | -13.9M | -15.2M | -18.6B |
| Capital Expenditure | 1.00 | 21.5K | 107K | 34.3K | 2.00 | 0.00 | 10.67 |
| Free Cash Flow | -38.7K | -3.20M | -13.8M | -13.5M | -13.9M | -15.2M | -18.6B |
| Ratios | |||||||
| ROE | -25.5% | -4.2% | -32.8% | -68.2% | -94.1% | -37.0% | -20.1% |
| ROA | -24.8% | -4.1% | -30.8% | -61.1% | -86.6% | -33.9% | -18.9% |
| Net Profit Margin | - | -14,430.5% | -2,864.3% | -3,280.5% | - | - | - |
| Debt to Equity | - | - | 0.01x | 0.00x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pasithea Therapeutics Corp dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | USD 360M | 328 | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Jan 2, 2024.
Who owns Pasithea Therapeutics Corp
- Insiders 1.12%
- Institutions 59.91%
- Public & others 38.98%
- Shares outstanding 33.4M
- Free float 26.0M
Top funds holding KTTA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| AdvisorShares Psychedelics ETF | 329K | 0.99% | -25.45% | Oct 2026 |
| Fidelity Extended Market Index | 151K | 0.45% | +163.23% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 13.4K | 0.04% | 0.00% | Aug 2026 |
| Fidelity Series Total Market Index | 7.97K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding KTTA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Cable Car Capital LLC | 3.00M | 8.98% | +148.68% | Jun 2026 |
| Stonepine Capital Management Llc | 2.20M | 6.59% | +164.82% | Jun 2026 |
| Jupiter Topco LLC | 2.10M | 6.28% | 0.00% | Jun 2026 |
| Adage Capital Partners Gp LLC | 2.10M | 6.28% | 0.00% | Jun 2026 |
| Opaleye Management Inc | 2.05M | 6.14% | 0.00% | Jun 2026 |
| Ameriprise Financial Inc | 1.86M | 5.58% | +38.02% | Jun 2026 |
| Squadron Capital Management LLC | 1.00M | 2.99% | -52.38% | Jun 2026 |
| AdvisorShares Investments, LLC | 938K | 2.81% | +177.79% | Jun 2026 |
| Vivo Capital, LLC | 465K | 1.39% | -77.83% | Jun 2026 |
| Persistent Asset Partners Limited | 291K | 0.87% | 0.00% | Jun 2026 |
| UBS Group AG | 188K | 0.56% | +619.38% | Jun 2026 |
| XTX Topco Ltd | 128K | 0.38% | +277.98% | Jun 2026 |
| Vanguard Capital Management, LLC | 126K | 0.38% | +134.65% | Jun 2026 |
| Geode Capital Management, LLC | 83.9K | 0.25% | -19.36% | Jun 2026 |
| Two Sigma Investments LLC | 64.2K | 0.19% | +204.77% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 43.9K | 0.13% | 0.00% | Jun 2026 |
| Northern Trust Corp | 31.4K | 0.09% | +62.12% | Jun 2026 |
| Jump Financial LLC | 29.4K | 0.09% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 8.84K | 0.03% | +376.70% | Jun 2026 |
| Hurley Capital, LLC | 7.00K | 0.02% | +89.75% | Jun 2026 |
Pasithea Therapeutics Corp company profile
- Company name
- Pasithea Therapeutics Corp
- Ticker
- KTTA.US
- Exchange
- USA Stocks
- Listed since
- Sep 15, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Fiscal year end
- December
- Address
- 1111 Lincoln Road, Miami Beach, FL, United States, 33139
- Phone
- 786 977 3380
- Website
- pasithea.com
About Pasithea Therapeutics Corp
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Pasithea Therapeutics Corp management
4- Dr. Lawrence Steinman BA, M.D., Ph.D.Co-Founder & Executive Chairman · born 1948
- Dr. Tiago Reis Marques M.D., Ph.D.CEO & Director · born 1977
- Mr. Daniel H. SchneidermanChief Financial Officer · born 1978
- Dr. Kartik Krishnan M.D., Ph.D.Chief Medical Officer · born 1971